BREAST CANCER


ADVANCE -Randomized Trial of SPI-2012 Versus Pegfilgrastim in the Management of Chemotherapy Induced Neutropenia in Breast Cancer Patients Receiving Docetaxel and Cyclophosphamide (TC)
  • To Find Out More Click Here.


GENITOURINARY/GYNECOLOGICAL CANCER


PRIME - Immune Monitoring Protocol in men with prostate cancer enrolled in a clinical trial of Sipuleucel-T
  • To Find Out More Click Here.

PREDICT - A Study to Evaluate Characteristics Predictive of a Positive Imaging Study for Distant Metastases in Patients with Castration-Resistant Prostate Cancer
  • To Find Out More Click Here.

IMVigor - A phase III, Multi-Center, Open-Label, Randomized study of Atezolizumab (Anti-PD-L1) versus observation as adjuvant therapy in patients with high-risk, muscle-invasive bladder cancer after cystectomy.
  • To Find Out More Click Here.

CA209374 - A Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects with Advanced or Metastatic Renal Cell Carcinoma
  • To Find Out More Click Here.

 

KEYNOTE 426 - A Phase III Randomized, Open-Label Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475/Keytruda) in Combination wtih Axitinib versus Sunitinib Monotherapy as a First-Line Treatment for Locally Advanced or Metastatic Renal Cell Carcinoma.

  • To Find Out More Click Here.

HEMATOLOGIC CANCER


CONNECT MDS/AML - The Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry
  • To Find Out More Click Here.

MAGNIFY - Phase III Randomized study of lenalidomide (CC-5013) plus rituximab maintenance therapy followed by lenalidomide single-agent maintenance versus rituximab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma.
  • To Find Out More Click Here.

GENUINE - A Phase 3, Randomized Study to Assess the Efficacy and Safety of Ublituximab in Combination with Ibrutinib Compared to Ibrutinib Alone, in patients with Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL)
  • To Find Out More Click Here.

 

informCLL- A Disease Registry for Patients with Chronic Lymphocytic Leukemia

  • To Find Out More Click Here.

 

CA209602 - An Open-Label, Randomized Phase 3 Trial of Combinations of Nivolumab, Elotuzumab, Pomalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma

  • To Find Out More Click Here.

 

UNITY 304/204 - A Phase 3, Randomized, Study to Assess the Efficacy and Safety of Ublituximab in Combination wtih TGR-1202 Compared to Obinutuzumab in Combination with Chlorambucil in Patients with Chronic Lymphocytic Leukemia (CLL)


LUNG CANCER


GO29527 - A Phase III, Open-Label, Randomized Study To Investigate The Efficacy And Safety Of Atezolizumab (ANTI-PD-L1 Anti-body) Compared With Best Supportive Care Following Adjuvant Cisplatin-Based Chemotherapy In Patients With Completely Resected Stage IB-IIIA Non-Small Cell Lung Cancer
  • To Find Out More Click Here.
 
GO29537 - A Phase III, Multi-Center, Randomized, Open-Label STudy Evaluating The Efficacy adn Safety of MPDL3280A (ANTI-PD-L1 Antibody) In Combination With Carboplatin + Nab-Paclitaxel For Chemotherapy-Naive Patients With Stage IV Non-Squamous NSCLC
  • To Find Out More Click Here.

 CA209370 - A Master Protocol of Phase 1/ 2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-Line Treatment Alone or in Combination with Standard of Care Therapies.
  • To Find Out More Click Here


OTHER


SIGNATURE - Modular phase II study to link targeted therapy to patients with pathway-activated tumors
  • To Find Out More Click Here.

CLDK378AUS23 - Module 7 - Ceritinib (LDK378) for patients whose tumors have aberrations in ALK or ROS1
  • To Find Out More Click Here.